The correlation between NAFLD and serum uric acid to serum creatinine ratio.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
05
2023
accepted:
01
07
2023
medline:
21
7
2023
pubmed:
18
7
2023
entrez:
18
7
2023
Statut:
epublish
Résumé
With the prevalence of non-alcoholic fatty liver disease (NAFLD) increasing worldwide, many noninvasive techniques have been used to improve its diagnosis. Recently, the serum uric acid/creatinine (sUA/sCr) ratio was identified as an indicator of fatty liver disease. Therefore, we examined the relationship between sUA/sCr levels and ultrasound-diagnosed NAFLD in Korean adults. This study included 16,666 20-year-olds or older who received health checkups at a university hospital's health promotion center from January to December 2021. Among them, 11,791 non-patients with and without NAFLD were analyzed, excluding those without abdominal ultrasound, those without data on fatty liver, cancer, or chronic kidney disease severity, those with a history of alcohol abuse, and those with serum hs-CRP <5 mg/L. The odds ratio (OR) and 95% confidence interval (CI) of the sUA/sCr ratio according to the presence or absence of fatty liver disease and severity were calculated after correcting for confounding variables using logistic regression analysis. The receiver operating characteristic (ROC) curve and area under the curve (AUC) of the sUA/sCr ratio confirmed and compared the sensitivity and specificity of NAFLD and serum uric acid. sUA/sCr increased with fatty liver severity, and the post-correction OR in the NAFLD group was 1.183 (95% CI: 1.137-1.231) compared to the group without NAFLD. Concerning the fatty liver severity, the post-correction OR in the mild NAFLD group increased to 1.147 (95% CI: 1.099-1.196), and that in the moderate-to-severe NAFLD group increased to 1.275 (95% CI: 1.212-1.341) compared to the group without NAFLD. The sensitivity of sUA/sCr to fatty liver severity was 57.9% for the non-NAFLD group, 56.7% for the mild NAFLD group, and 59.0% for the moderate-to-severe NAFLD group; the specificity of sUA/sCr to fatty liver severity 61.4% for the non-NAFLD group, 57.3% for the mild NAFLD group, and 65.2% for the moderate-to-severe NAFLD group. NAFLD severity is associated with sUA/sCR.
Sections du résumé
BACKGROUND
With the prevalence of non-alcoholic fatty liver disease (NAFLD) increasing worldwide, many noninvasive techniques have been used to improve its diagnosis. Recently, the serum uric acid/creatinine (sUA/sCr) ratio was identified as an indicator of fatty liver disease. Therefore, we examined the relationship between sUA/sCr levels and ultrasound-diagnosed NAFLD in Korean adults.
METHODS
This study included 16,666 20-year-olds or older who received health checkups at a university hospital's health promotion center from January to December 2021. Among them, 11,791 non-patients with and without NAFLD were analyzed, excluding those without abdominal ultrasound, those without data on fatty liver, cancer, or chronic kidney disease severity, those with a history of alcohol abuse, and those with serum hs-CRP <5 mg/L. The odds ratio (OR) and 95% confidence interval (CI) of the sUA/sCr ratio according to the presence or absence of fatty liver disease and severity were calculated after correcting for confounding variables using logistic regression analysis. The receiver operating characteristic (ROC) curve and area under the curve (AUC) of the sUA/sCr ratio confirmed and compared the sensitivity and specificity of NAFLD and serum uric acid.
RESULTS
sUA/sCr increased with fatty liver severity, and the post-correction OR in the NAFLD group was 1.183 (95% CI: 1.137-1.231) compared to the group without NAFLD. Concerning the fatty liver severity, the post-correction OR in the mild NAFLD group increased to 1.147 (95% CI: 1.099-1.196), and that in the moderate-to-severe NAFLD group increased to 1.275 (95% CI: 1.212-1.341) compared to the group without NAFLD. The sensitivity of sUA/sCr to fatty liver severity was 57.9% for the non-NAFLD group, 56.7% for the mild NAFLD group, and 59.0% for the moderate-to-severe NAFLD group; the specificity of sUA/sCr to fatty liver severity 61.4% for the non-NAFLD group, 57.3% for the mild NAFLD group, and 65.2% for the moderate-to-severe NAFLD group.
CONCLUSION
NAFLD severity is associated with sUA/sCR.
Identifiants
pubmed: 37463147
doi: 10.1371/journal.pone.0288666
pii: PONE-D-23-16163
pmc: PMC10353803
doi:
Substances chimiques
Uric Acid
268B43MJ25
Creatinine
AYI8EX34EU
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0288666Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright: © 2023 Choi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS One. 2010 Jul 14;5(7):e11578
pubmed: 20644649
Metab Syndr Relat Disord. 2021 Mar;19(2):70-75
pubmed: 33314991
J Clin Transl Hepatol. 2019 Dec 28;7(4):362-370
pubmed: 31915606
Metab Syndr Relat Disord. 2009 Aug;7(4):305-14
pubmed: 19558267
N Engl J Med. 2002 Apr 18;346(16):1221-31
pubmed: 11961152
J Clin Ultrasound. 1996 Jan;24(1):25-9
pubmed: 8655663
Curr Vasc Pharmacol. 2018;16(3):269-275
pubmed: 28676018
Front Endocrinol (Lausanne). 2020 Nov 19;11:600472
pubmed: 33329401
World J Gastroenterol. 2014 Jul 14;20(26):8377-92
pubmed: 25024596
Glob Health Promot. 2020 Sep;27(3):44-55
pubmed: 31375056
Rev Assoc Med Bras (1992). 2021 Apr;67(4):549-554
pubmed: 34495059
Am J Physiol Renal Physiol. 2006 Mar;290(3):F625-31
pubmed: 16234313
Nat Rev Rheumatol. 2015 Nov;11(11):649-62
pubmed: 26150127
Lab Invest. 2014 Oct;94(10):1114-25
pubmed: 25111690
J Physiol Biochem. 2022 May 12;:
pubmed: 35546386
PLoS One. 2019 Dec 19;14(12):e0226375
pubmed: 31856189
Clin Mol Hepatol. 2021 Jul;27(3):363-401
pubmed: 34154309
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
BMC Gastroenterol. 2022 Sep 14;22(1):419
pubmed: 36104672
Ann Clin Lab Sci. 2019 Mar;49(2):218-223
pubmed: 31028067
BMC Med. 2017 Jul 3;15(1):123
pubmed: 28669352
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
J Biol Chem. 2012 Nov 23;287(48):40732-44
pubmed: 23035112
J Clin Lab Anal. 2022 Aug;36(8):e24590
pubmed: 35808891
Hepatology. 2012 Jun;55(6):2005-23
pubmed: 22488764
Hepatology. 2003 Apr;37(4):917-23
pubmed: 12668987
Lancet. 2005 Apr 16-22;365(9468):1415-28
pubmed: 15836891
J Obes Metab Syndr. 2021 Jun 30;30(2):81-92
pubmed: 34045368
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
J Hepatol. 2009 May;50(5):1029-34
pubmed: 19299029
Gut Liver. 2010 Sep;4(3):378-83
pubmed: 20981217
Hypertension. 2003 Jun;41(6):1183-90
pubmed: 12707287